TheraCryf (LSE:TCF) Stock Based Compensation: £0.20 Mil (TTM As of Sep. 2025)


What is TheraCryf Stock Based Compensation?

TheraCryf LSE:TCF Stock Based Compensation is £0.20 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

TheraCryf's Stock Based Compensation for the six months ended in Sep. 2025 was £0.10 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 was £0.20 Mil.

TheraCryf Stock Based Compensation Related Terms

TheraCryf Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for TheraCryf's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf Stock Based Compensation Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 0.15 0.16 0.14 0.12

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.08 0.02 0.10 0.10

TheraCryf Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.20 Mil.

What does a Stock Based Compensation of £0.20 Mil mean?
TheraCryf (LSE:TCF) has a Stock Based Compensation of £0.20 Mil as of Sep. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for TheraCryf and its competitors.
Is TheraCryf's Stock Based Compensation too high?
TheraCryf's current Stock Based Compensation is £0.20 Mil.
How does TheraCryf's Stock Based Compensation compare to VRTX and REGN?
TheraCryf's Stock Based Compensation of £0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for TheraCryf and its competitors. TheraCryf's current Stock Based Compensation is £0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current Stock Based Compensation of £0.20 Mil. The current Stock Based Compensation is £0.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current Stock Based Compensation is £0.20 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.